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ABSTRACT
Allograft rejection after renal transplantation remains a challenge to overcome. Interleukin (IL)-21, a cytokine
with pleiotropic effects, maintains immune homeostasis post-transplantation. Here, we report higher levels of
IL-21 in kidney transplant recipients with non-rejection (NR) than in recipients with T cell-mediated rejection
(TCMR, P < 0.001) and antibody-mediated rejection (ABMR, P = 0.005). We observed a negative correlation
between IL-21 and creatinine (Cr) levels (P = 0.016). The receiving operating characteristic (ROC) curve showed
a promising diagnostic value of IL-21 to identify acute rejection with an area under the curve (AUC) of 0.822 (P <
0.001). In contrast, exogenous administration of IL-21 accelerated acute rejection in a comparative translational
kidney transplant (KT) mouse model. Reduced IL-21 levels in the peripheral blood were observed in KT mice
after IL-21 injection. Further analysis revealed that increased IL-21 levels in the spleen induced proliferation of
CD4+ T cells and CD19+ B cells after IL-21 treatment. Our findings suggest a critical function of IL-21 in kidney
transplantation and the potential involvement of the IL-21/IL-21R pathway in acute rejection management.

INTRODUCTION
Allograft rejection remains one of the major barriers to
the long-term survival of the graft. More potent immuno-
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suppressive drugs and better histocompatibility between
recipients and donors have altered the characteristics of
allograft rejection. The risk of rejection within 1 year
after kidney transplantation has declined to less than
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15% [1]. However, the overall graft survival rates have
still not improved due to the intractability of rejection
[2]. Based on different clinicopathologies, rejection
could be divided into T cell-mediated rejection (TCMR)
and antibody-mediated rejection (ABMR) [1]. Patients
with emerging rejection face an increased risk of graft
failure, especially ABMR [3, 4].
Failure of immunosuppression and activation of the
immune system against the allograft in recipients are
majorly responsible for its rejection [1, 5]. The
involvement of innate and adaptive immunity in TCMR
and ABMR has been demonstrated by numerous
clinical and animal studies [6–8]. Apart from the signals
transduced by exogenous antigens and costimulatory
molecules, cytokines secreted by immune cells,
identified as “signal 3”, can activate the immune
system, particularly T and B cells [9, 10]. Interleukin
(IL)-21 is an important “signal 3” molecule that exerts
its effects on T and B cells via autocrine and paracrine
signaling.
IL-21 is a proinflammatory cytokine involved in several
immune dysfunction diseases. It is one of the main
cytokines secreted by T follicular helper (Tfh) cells [11,
12], which stimulate the differentiation of B cells into
antibody-secreting plasma cells and have been reported
to be involved in autoimmune disorders [13]. Weinstein
et al. revealed the successive secretion pattern of IL-21
and IL-4 by Tfh cells in germinal centers (GCs) using a
double reporter mouse model [14] and highlighted the
involvement of IL-21 in T and B cell crosstalk.
Moreover, genome-wide association studies and animal
studies have demonstrated a high expression of IL-21 in
patients with autoimmune diseases, such as systemic
lupus erythematosus [15, 16], rheumatoid arthritis [17],
type 1 diabetes [18], and celiac disease [19]. The study
of early onset of inflammatory bowel disease in patients
deficient for IL-21 [20] has advanced the understanding
of IL-21 as a proinflammatory cytokine.
Increased levels of IL-21 in hyperplastic follicles were
observed in a rhesus macaque kidney transplant model
with ABMR [9]. The antagonist of IL-21 receptor (IL21R) was reported to block B cell differentiation [21].
Another study reported that the blocking of IL-21R
ameliorated allograft rejection in a mouse skin
transplant model [22]. Further, the role of IL-21 in
immune tolerance in kidney transplant recipients is
dependent on granzyme B (GZMB)+ B cells [23].
Previous studies have primarily focused on the effect of
IL-21R blocking on transplantation or its in vitro
effects. In the present study, we demonstrated the
involvement of IL-21 in acute rejection after kidney
transplantation. A unique cytokine profile was
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identified in patients with or without acute rejection
after kidney transplantation. Surprisingly, higher levels
of IL-21, accompanied by a comparable class switching
rate of antibodies, were closely related with a stable
immune status in patients after transplantation. To
further directly investigate the function of IL-21 in
maintaining a stable immune status, we generated a
mouse model of kidney transplant (KT) with tail vein
injection of exogenous IL-21. Intriguingly, histopathological analysis revealed emerging acute rejection
with an increased number of B cells after injection of
exogenous IL-21. We believe that IL-21 can serve as a
potential therapeutic target for acute rejection.

RESULTS
Patient characteristics
The demographic characteristics of different subgroups
are summarized in Table 1. There was no difference
among non-rejection (NR), TCMR, and ABMR cohorts
regarding the donor-associated parameters, recipient’s
age, primary kidney disease, dialysis, delayed graft
function (DGF) rate, or HLA-mismatch (HLA-MM).
Considerable differences in recipient’s gender (P =
0.025) and induction (P = 0.001) were noted among the
three cohorts.
Higher peripheral blood IL-21 levels in stable
transplant recipients
The serum cytokine levels of recipients with or without
acute rejection after kidney transplantation were
measured using the Luminex assay. Levels of major
proinflammatory cytokines, such as IL-2, IL-4, and IL-6
(Figure 1A–1C), were slightly higher in acute rejection
patients than in immune stable patients after kidney
transplantation. Unexpectedly, the levels of IL-21,
which is widely considered as a driving factor of GC B
cell differentiation, were lower in acute rejection
patients (11.02±0.29 pg/mL) than in immune stable
patients (18.21±2.00 pg/mL, P < 0.001) (Figure 1G).
Similarly, the circulating levels of interferon (IFN)-γ in
acute rejection patients (13.18±2.02 pg/mL) were lower
than in immune stable patients (29.41±6.59 pg/mL, P =
0.012) (Figure 1I). Comparable levels of IL-10, IL-12,
IL-17, IL-27, and tumor necrosis factor (TNF)-α (Figure
1D–1F, 1H, and 1J) were observed between recipients
with and without acute rejection.
Distinct circulating cytokine levels in different types
of rejection
To further characterize and compare acute rejection
subgroups, we divided the acute rejection cohort into
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Table 1. Demographics of patients.
NR
(N=30)
Donor associated parameters
Age (years)
43.47±2.66
Serum creatinine (mol/L)
92.36±11.48
Donor type (DCD/LD)
19/11
Donor sex(M/F)
22/8
Recipients associated parameters
Age (year)
41.27±1.88
Sex (M/F)
10/20
Kidney primary disease
Chronic kidney disease
25
IgA nephropathy
1
Lupus nephritis
0
Polycystic kidney disease
0
Diabetic nephropathy
0
Others
4
Dialysis
Hemodialysis
20
Peritoneal dialysis
10
None
0
DGF
1/29
Induction
Simulect
9
ATG
5
Rituximab
0
None
16
HLA-MM
2.63±0.23
Stable creatinine
92.36±11.48
Highest creatinine
92.36±11.48
DSA
0
Time of rejection
NA

AR
(N=36)

TCMR
(N=28)

ABMR
(N=8)

Pa

Pb

45.33±1.90
99.19±12.98
22/14
24/12

45.39±2.18
101.03±14.62
19/9
19/9

45.13±4.12
92.75±29.97
3/5
5/3

0.844
0.892
0.291
0.807

0.162
0.286
0.853
0.557

36.94±1.79
22/14

38.00±2.08
16/12

33.25±3.38
6/2

0.511
0.054
0.697

0.791
0.025
0.466

25
1
1
3
1
5

20
1
1
2
1
3

5
0
0
1
0
2
0.495

0.480

20
15
1
31/5

14
13
1
5/23

6
2
0
0/8

0.100
0.004

0.137
0.001

19
13
1
3
2.61±0.22
149.03±16.04
248.25±24.37
8
575.14±114.03

13
11
1
3
2.68±0.27
138.75±10.48
235.75±25.80
0
440.57±103.28

6
0
2
0
2.38±0.26
185.00±34.18
292.00±63.42
8
1046.13±336.15

0.837
0.011
<0.001
0.006
NA

0.924
0.324
0.004
<0.001
NA

NR, no rejection; AR, acute rejection; TCMR, T cell mediated rejection; ABMR, antibody mediated rejection; DGF, delayed
graft function; ATG, anti-thymocyte globulin; HLA-MM, HLA-mismatch; DSA, donor specific antibody; Pa, P value represents
the difference between NR and AR; Pb, P value represents the difference between NR, TCMR, and ABMR, using one-way
ANOVA.

TCMR and ABMR cohorts based on the histological
evidence provided by Banff in 2017 [24]. We found that
serum IL-2 levels were higher in the ABMR cohort than
in the NR (P = 0.014) or TCMR (P = 0.016) cohort
(Figure 2A). By contrast, serum levels of IL-4, IL-6
(Figure 2B and 2C), IL-12, IL-27, and TNF-α
(Supplementary Figure 1A–1C) showed no detectable
difference among the three cohorts. The IL-21 levels in
the NR cohort were higher than in both TCMR
(10.98±0.35 pg/mL, P < 0.001) and ABMR (11.15±0.56
pg/mL, P = 0.008) cohorts (Figure 2F). However, no
difference was found between the two rejection
subgroups. Elevated levels of IL-10 were present in
ABMR cohort, and slightly reduced levels of IL-17 and
IFN-γ were present in the TCMR cohort (Figure 2D, 2E
and Supplementary Figure 1D).
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Cytokines are characterized as “signal 3” in T and B
cell crosstalk, which promotes B cell differentiation,
maturation, and class switching. The class switching
rate of B cells was measured by detecting the levels of
serum immunoglobulins. No difference was found in
the levels of IgM and IgG1-3 in the three cohorts
(Figure 3A–3C). The circulating levels of IgG4 were
high in the ABMR cohort (P = 0.044 vs. NR cohort and
P = 0.012 vs. TCMR cohort) (Figure 3D).
Serum IL-21 levels negatively correlate
allograft function

with

The correlation between circulating cytokine levels and
allograft function was analyzed (Supplementary Table
1). Linear regression analysis revealed a good
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Figure 1. Higher peripheral blood IL-21 levels in stable transplant recipients. Absolute concentration (pg/mL) of serum IL-2, IL-4, IL6, IL-10, IL-12, IL-17, IL-21, IL-27, IFN-γ, and TNF-α (A–J) in recipients with (n = 36) and without (n = 30) active rejection after kidney
transplantation. Red dash dot line represents the mean value. *P < 0.05 and **P < 0.01 compared with NR cohorts. IL, interleukin; IFN,
interferon; NR, non-rejection; TNF, tumor necrosis factor.

Figure 2. Distinct circulating cytokine levels in different types of rejection. Serum levels of IL-2, IL-4, IL-6, IL-10, IL-17, and IL-21 (A–F)
in patients in NR (n = 30), TCMR (n = 28) and ABMR (n = 8) cohorts were measured before anti-rejection therapy. Dash dot line represents the
mean value. *P < 0.05, **P < 0.01, and ***P < 0.001. IL, interleukin; ABMR, antibody-mediated rejection; NR, non-rejection; TCMR, T cellmediated rejection.
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correlation of serum IL-21 (ρ = −0.018, P = 0.016) and
TNF-α (ρ = 0.006, P < 0.001) (Figure 4A and 4B) levels
with serum creatinine (Cr), indicating that circulating
cytokines could be a potential biomarker for monitoring
renal dysfunction. The diagnostic capacity of IL-21 and
TNF-α in distinguishing allograft rejection was measured
using the receiver operating characteristic (ROC) curve.
The area under the curve (AUC) for serum IL-21 levels
was 0.822 (P < 0.001), with sensitivity and specificity of
72.22% and 80%, respectively, and a cut-off value of
11.47 pg/mL (Figure 4C). TNF-α exhibited less
diagnostic capacity in rejection diagnosis with an AUC of
0.636 (P = 0.059) (Figure 4D).
Exogenous IL-21 promotes allograft rejection in
mice
To explore the function of IL-21 in transplant
immunobiology, we generated KT mice with tail vein
injection of exogenous IL-21 on days 0, 2, 4, and 6
post-transplantation (Figure 5A). Hematoxylin and
eosin (HE), periodic acid-Schiff (PAS), and Masson’s
staining revealed enhanced infiltration of inflammatory
cytokines and fibrosis in the allograft that worsened
with IL-21 administration (Figure 5B). Next, the

cytokine levels in the transplanted kidney were
estimated; similar to the inflammatory infiltration, the
expression of proinflammatory cytokines such as IFN-γ
(P < 0.001 vs. control group and P = 0.008 vs. KT
group) and TNF-α (P = 0.011 vs. control group) was
upregulated (Figure 5C). The IL-21 (P < 0.001 vs.
control group) and IL-4 (P = 0.011 vs. control group)
levels in the transplanted kidney reduced (Figure 5D).
No difference was found in the levels of IL-10, IL-6,
and IL-17 in the transplanted kidney among the three
groups (Figure 5E).
Next, we evaluated the histopathology of the allograft.
A heavy deposit of linear C4d in peritubular capillaries
(P = 0.016 vs. control group) after IL-21 injection
(Figure 6A and 6B) was observed. More severe
allograft injury, including glomerulitis, tubulitis, and
interstitial inflammation, was observed in KT mice with
IL-21 treatment (Figure 6C, 6D, and 6E). Peritubular
capillary and intimal arteritis showed no difference
(Figure 6F and 6G). The donor-specific antibody (DSA)
titers in the kidney recipients were measured by flow
cytometry. Higher DSA titers were observed after
IL-21 administration (P = 0.008 vs. control group)
(Supplementary Figure 2).

Figure 3. No significant difference in antibody class switching between NR and active rejection cohorts was observed. (A, B)
Levels of IgM and IgG1-4 in NR (n =30) and rejection (n = 35) groups. (C, D) Levels of IgM and IgG1-4 in NR (n =30), TCMR (n = 28), and ABMR
(n = 7) cohorts. The dash dot line represents the mean value. The difference among the three subgroups was analyzed using one-way ANOVA.
*P < 0.05. ABMR, antibody-mediated rejection; ANOVA, analysis of variance; NR, non-rejection; TCMR, T cell-mediated rejection.
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Exogenous IL-21 alters cytokine and IL-21R
expression in mice after kidney transplantation
The cytokine levels in the peripheral blood and spleen of
KT mice were measured on the day mice were sacrificed.
Interestingly, the peripheral IL-21 levels in mice after
administration of exogenous IL-21 were lower than in
mice injected with phosphate-buffered saline (PBS) (P =
0.004) and control groups (P < 0.001) (Figure 7A).
Moreover, the IL-6 levels increased after IL-21 treatment,
but no major difference was found (Figure 7B). No
difference was found among the levels of IL-2, IL-4, IL10, and IL-17 (Figure 7A and 7B), whereas an increased
level of inflammatory cytokine TNF-α was observed (P =
0.011 vs. control group) (Supplementary Figure 3A). A
substantial increase in IL-21 levels in the spleen was
observed after administration of exogenous IL-21 (P =
0.040 vs. PBS injection) (Figure 7D), with a higher
expression of IL-21R (P = 0.021 vs. PBS injection and P
= 0.011 vs. control group) (Figure 7C and Supplementary
Figure 3C–3E). Furthermore, compared with the other
two groups, IL-10 levels were higher in the KT group (P
= 0.018 vs. control group, P = 0.014 vs. IL-21+KT group)
(Figure 7E).

Exogenous IL-21 induces B and T cell proliferation
Flow cytometry was performed to analyze B and T cells
in the peripheral blood and spleen. After kidney
transplantation, the number of B cells slightly increased,
and the number was higher after IL-21 stimulation both
in the peripheral blood (P < 0.001 vs. control group, P =
0.008 vs. KT group) and the spleen (P = 0.004 vs.
control group) (Figure 8A, 8C). Furthermore, the
number of CD4+ T cells in the peripheral blood steadily
increased in kidney transplanted mice administered IL21 than in those administered PBS (P = 0.003) (Figure
8B, 8D). The number of CD4+ T cells was more
variable in the spleen, with no major difference (Figure
8B, 8D).

DISCUSSION
In the present study, we measured the serum levels of
IL-21 in acute rejection patients post kidney
transplantation and assessed its function in a mouse KT
model. Reduced serum levels of IL-21 were detected in
both TCMR and ABMR cohorts as compared to
immune stable recipients. Serum IL-21 levels

Figure 4. Serum IL-21 levels correlate with allograft function. Correlation of serum IL-21 and TNF-α levels with serum Cr levels
(A, B). The ROC curves of IL-21 and TNF-α to investigate their ability to distinguish between rejection and NR recipients (C, D). Cr, creatinine;
IL, interleukin; NR, non-rejection; ROC, receiver operating characteristic; TNF, tumor necrosis factor.

www.aging-us.com

18401

AGING

Figure 5. Exogenous IL-21 promotes inflammatory infiltration in the allograft. C57BL/6 mice received renal allografts from Balb/c
mice. Kidney recipients were injected recombinant murine IL-21 (10 μg in 100 μL PBS; n = 9) or 100 μL PBS (n = 7) in the tail vein on days 0, 2,
4, and 6 after transplantation (A). Blank control (n = 3) of mice without transplantation received tail vein injection of PBS simultaneously. All
animals were sacrificed 7 days post-transplantation. Histologic evaluation of kidney allografts from Control, KT, and IL-21+KT recipients on
day 7 post-transplantation stained with (B) H&E, PAS, and Masson’s stains (scale bar: 100μm). Levels of (C) IFN-γ and TNF, (D) IL-21, IL-2, and
IL-4, (E) IL-10, IL-6, and IL-17 in the transplanted kidney of KT subgroups and primary kidney of Control are shown. Values represent mean
(±SEM). *P < 0.05, **P < 0.01, and ***P < 0.001. H&E, hematoxylin and eosin; IL, interleukin; PAS, periodic acid–Schiff; PBS, phosphatebuffered saline; KT, kidney transplant; SEM, standard error of the mean.
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negatively correlated with allograft function, showing a
promising diagnostic value with an AUC of 0.822 (P <
0.001). Interestingly, no difference in class switching was
found. Administration of exogenous IL-21 accelerated
allograft rejection in KT mice, accompanied by reduced
levels of IL-21 in the peripheral blood and enrichment of
IL-21 in the spleen. Further analysis revealed IL-21induced enhanced proliferation of T and B cells in the
spleen resulting in acute humoral rejection.
IL-21 is a cytokine with pleiotropic effects; it maintains
the immune homeostasis including in patients after solid
organ transplantation [25]. It is identified as the most
potent plasma cell inducer in vitro [26]. IL-21 activates
both Tfh cells [15, 27] and B cells in GCs via autocrine
and paracrine signaling. Similarly, elevated levels of IL21 in the GC of ABMR recipients suggest its possible
function in the GC during the onset of active rejection

[9]. Blocking of IL-21 activity ameliorated the graftversus-host disease after hematopoietic stem cell
transplantation [28].
Intriguingly, IL-21 can also mediate immunosuppressive effect. Studies have reported that IL-21
induces apoptosis of immunocytes by upregulating the
expression of transcription factor Bcl-2 [29, 30].
Chesneau et al. recently reported the function of IL-21dependent GZMB+ B cells in maintaining immune
tolerance in kidney transplant recipients. Moreover,
they observed elevated secretion of IL-21 by T cells
after stimulation by B cells in tolerant recipients [23].
Their findings were mainly based on in vitro
experiments and lacked the study of serum cytokine
levels in patients. In the present study, we measured the
cytokine levels in kidney transplant recipients. Elevated
levels of IL-21 were observed in patients with stable

Figure 6. Exogenous IL-21 promotes active kidney rejection in mice. (A and B) Expression of C4d in the allograft (scale bar: 250μm).
Histopathology scores of glomerulities, tubulitis, I, PTC, and V (C–G) of the kidney allografts from Control, KT, and IL-21+KT recipients. Values
represent mean (±SEM). *P < 0.05, **P < 0.01, and ***P < 0.001. PTC, peritubular capillaritis; I, interstitial inflammation; V, intimal arteritis;
IL, interleukin; KT, kidney transplant; SEM, standard error of the mean.
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immune status. Serum IL-21 levels negatively
correlated with serum Cr levels, whereas with an AUC
of 0.822 (P < 0.001), IL-21 measurement did not
outperform the diagnostic capacity of Cr (AUC: 0.989,
P < 0.001).
IL-21 is involved in antibody class switching of B cells
in both human and mouse systems to activate the
humoral response. The IgG production level was
reported to be slightly lower in IL-21R-deficient mice
[31]. However, the blocking of both IL-4 and IL-21R
severely impaired the IgG response [31]. In addition, we
evaluated the rate of antibody class switching in patients
post kidney transplantation; it was largely intact when
acute rejection occurred. Because the serum IL-4 levels
were comparable among NR, TCMR, and ABMR
cohorts, this result was expected.
Patients with stable graft function for more than 5 years
were enrolled in the NR cohort. In contrast, the average
time of rejection in the total rejection group was
575.14±114.03 days. NR and rejection groups were not
matched with respect to the time from transplantation
due to insufficient follow-up durations to define NR.
However, no correlation was observed between the time
of rejection and cytokine and antibody levels (data not
presented).

IL-21 is a well-conserved gene [32]. The distribution of
its effector IL-21R and the downstream signaling
pathways, through which it regulates the differentiation
and functions of lymphoid cells responsible for humoral
response, are similar in human and mice [33]. Hence,
we established a KT mouse model to further directly
address the role of IL-21 in kidney transplantation.
Exogenous IL-21 was injected into KT mice to mimic
the serum IL-21 levels in immune stable patients.
However, unexpectedly, the injection of exogenous IL21 induced enhanced inflammatory infiltration, C4d
deposit, and allograft injury including glomerulitis,
tubulitis, and interstitial inflammation in the
transplanted kidney. These findings suggest that
exogenous IL-21 induced a higher rate of rejection
instead of maintaining immune tolerance, a finding
considerably different from that reported by previous
studies [9, 22].
IL-21 exerts its effect on a variety of immune cells via
the IL-21R to promote cell differentiation and
maturation [33]. It is involved in the generation and
differentiation of Tfh cells through an autocrine loop
and amplifies its secretion [15, 27]. Moreover, it
augments the proliferation, maturation, and differentiation of B cells by upregulating transcription factors
such as Bcl-6 and Blimp-1 in the GC [13, 34]. In

Figure 7. Exogenous IL-21 alters cytokine and IL-21R expression in mice after kidney transplantation. The level of IL-21, IL-2, and
IL-4, and IL-10, IL-6, and IL-17A in the peripheral blood (A and B) and spleen (D and E) on day 7 post-transplantation was measured by CBA.
(C) Histologic evaluation of IL-21R expression in the spleen of subgroups. Values represent mean (±SEM). *P < 0.05, **P < 0.01, and ***P <
0.001. CBA, cytometric bead array; IL, interleukin; SEM, standard error of the mean.
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the present study, the administration of IL-21 led to the
corresponding increased IL-21R expression in the
spleen. The upregulated expression of IL-21R allows
IL-21 to perform its growth factor-like functions via the
IL-21/IL-21R signaling pathway. Furthermore, flow
cytometry was used to analyze the proportion of
immune cells in the peripheral blood and spleen of KT
mice after IL-21 injection. An increase in the number of
B cells in both peripheral blood and spleen was
observed, accompanied by an elevated number of CD4+
T cells in the peripheral blood.
Tfh cells are the primary source of serum IL-21,
whereas the ability of Tfh subsets to produce IL-21 is
variable. Recent studies have reported that Tfh cells can
be further divided into GC Tfh cells and peripheral Tfh

cells based on different locations [35]. The IL-21
secretion ability of GC Tfh cells is extremely low such
that little or no induction of IL-21 in antigen-specific
GC Tfh cells was detected in macaque studies [36–38],
whereas the peripheral Tfh cells have been reported to
secrete high levels of cytokines such as IL-21 [39]. We
detected decreased serum IL-21 levels in mice after KT
despite the administration of exogenous IL-21, which
was similar to the serum level of IL-21 in patients with
acute rejection after KT, with a notably higher level of
IL-21 in the spleen observed after IL-21 injection.
Besouw et al. recently reported a correlation between
increased donor-specific IL-21-producing cells,
especially circulating Tfh cells, and kidney graft
rejection [40]. Accumulation of Tfh cells in follicularlike structures of the transplanted kidney was reported

Figure 8. Exogenous IL-21 induces B cell and T cell proliferation. Flow cytometry analysis to measure CD19+ B (A) and CD4+ T (B)
lymphocytes in the peripheral blood and spleen of recipients and controls. Distribution of proportions of CD4 + T cells (C) and CD19+ B cells (D)
of total lymphocytes on day 7 post-transplantation. Boxes and whiskers represent minimum to maximum of all the data. **P < 0.01 and ***P
< 0.001 one-way ANOVA. ANOVA, analysis of variance; IL, interleukin.
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by Graav et al. [41]. This could be attributed to the fact
that during acute rejection onsets, peripheral IL-21producing Tfh cells enter into the spleen and allograft,
activating T and B cell proliferation and maturation by
secreting IL-21 in the GC or follicular-like structures,
leading to acute rejection.
The present study had certain limitations. First, the
number of patients enrolled in this study was relatively
low because of the low incidence rate of acute rejection
in our kidney disease center. As healthy volunteers do
not have alloantigens or take immunosuppressants, the
immune status of such population is considerably
different from that of kidney transplant recipients.
Although our study could not include healthy controls
due to their unwillingness to provide samples, we
believe the NR cohort used as the disease control should
be sufficient for studying transplant immunology
changes in allograft rejection. This is because the
immune status of the NR cohort is considerably closer
to that of rejection cohorts. Second, the present study
did not provide biopsy information of patients with
stable allograft function because patients refused to
undergo biopsy due to a Chinese tradition. Third,
although we studied the critical function of IL-21 in
kidney transplantation, the interpretation of results still
requires more clinical evidence.
In conclusion, we observed distinctly lower levels of
serum IL-21 in acute rejection patients, with a
diagnostic and therapeutic implication of IL-21 from a
precision medicine perspective. The mouse KT model
proved useful in conducting in vivo studies of IL-21
biology. The injection of exogenous IL-21 triggered
allograft rejection in kidney transplantation mice and
resulted in enrichment of IL-21 in the spleen. Flow
cytometry study revealed the proliferation of CD4+ T
and CD19+ B cells in the peripheral blood and spleen
when rejection occurred. These findings suggest the
involvement of IL-21 in transplant immunobiology,
highlighting its therapeutic potential in acute rejection.

The peripheral blood samples of patients in the NR
cohorts were collected during their routine follow-up
investigations. The peripheral blood samples of patients
in the acute rejection cohort were collected before renal
biopsy and anti-rejection treatment. Histopathology was
conducted by two experienced pathologists in our
hospital.
Detection of serum cytokine levels and isotype class
switching in serum
Serum levels of cytokines IL-2, IL-4, IL-6, IL-10, IL12, IL-17, IL-21, IL-27, IFN-γ, and TNF-α, and IgM
and IgG subsets were measured by the multiplex bead
immunoassay (HGAMMAG-301K-05, Millipore for
cytokine detection; LXSAHM-10, R&D system for
antibody detection, Shanghai Universal Biotech Co.,
Ltd) according to the manufacturer’s instructions.
Briefly, the beads with standards and samples were
incubated for 1 h at room temperature. The wells were
washed with wash buffer and incubated with primary
antibodies for 30 min. Afterward, the coated beads were
incubated with biotinylated antibodies for 30 min. The
analysis was performed using the Luminex system (X200).
Animals

MATERIALS AND METHODS
Patients
The study was approved by the Research Ethics
Committee of The First Affiliated Hospital, College of
Medicine, Zhejiang University (Hangzhou, China;
approval number: 2016-512). All patients provided
written informed consent. From September 2017 to
September 2018, a total of 66 peripheral blood samples
were collected from 66 patients after kidney
transplantation, of which 30 were NR, 28 were acute
TCMR, and 8 were active ABMR. Of the 28 patients in
the TCMR group, 12 patients belonged to grade IA, two

www.aging-us.com

patients belonged to grade IB, 13 patients belonged to
grade IIA, and 1 patient belonged to grade IIB. Patients
with stable allograft function (creatinemia < 150
mmol/L and proteinuria < 1g/24 h [23]), negative panel
reactive antibodies, and no BK virus infection for more
than 5 years post transplantation were enrolled into the
NR cohort. Patients with histological confirmation of
acute rejection were enrolled in the rejection cohort,
which was further divided into TCMR and ABMR
according to the Banff 2017 criterion [24]. Exclusion
criteria included acute infection, use of glucocorticoids,
or anti-thymocyte globulin (ATG) pulse in 3 months.
The characteristics of different subgroups are
summarized in Table 1.
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All protocols involving animals were approved by the
Institutional Animal Care and Utilization Committee of
The First Affiliated Hospital, College of Medicine,
Zhejiang University. The C57BL/6 and Balb/c mice
were purchased from the Laboratory Animal Center of
Zhejiang University. All mice were housed in sterile
microisolator cages. Eight-week-old male mice were
used in all experiments.
Kidney transplantation and treatment
The left kidney from Balb/c mice was transplanted
into C57BL/6 mice with anastomosis to the inferior
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vena cava and the recipient abdominal aorta, ureter
anastomosis to the bladder as previously described
[42]. The right kidney remained intact. Recombinant
murine IL-21 (BMS6021, eBioscience; 10 μg in 100
μL PBS) (n = 9) [43] or 100 μL PBS (n = 7) was
administered by tail vein injection into the recipients
at days 0, 2, 4, and 6 after transplantation (Figure 5A).
PBS was administered by tail vein injection into mice
without transplantation (blank control, n = 3)
simultaneously. All animals were sacrificed 7 days
post-transplantation.

Cytometric bead array
Cytokines from the peripheral blood, spleen, and
transplanted kidney were isolated as previously
described [47]. Cytokine levels in the peripheral blood
and spleen of mice after kidney transplantation were
measured by cytometric bead array (CBA). The spleen
and kidney tissues were mechanically homogenized,
and the supernatants were collected. The Mouse Soluble
Protein Master Buffer Kit and the appropriate CBA flex
sets Mouse Th1/Th2/Th17 Cytokine Kit (BD
Biosciences) were used to perform CBA analysis.

Histopathological analysis
Primary renal, spleen, and renal allograft tissue crosssections were fixed in 10% formalin and embedded in
paraffin. Five µm sections were cut with a Leica
CM1900 cryomicrotome (Leica Biosystems Division of
Leica Microsystems Inc.). The sections underwent
H&E, PAS, and Masson's staining for histological
evaluation. Immunochemistry staining was performed
following the manufacturer’s protocol. Briefly, sections
were deparaffinized by successively washing them with
xylene, 100% and 95% ethanol, and distilled water.
After antigen unmasking and blocking, the sections
were incubated with anti-C4d antibody (HP8033;
Hycult Biotech, USA) or anti-IL21R antibody (ab5980;
Abcam, UK) overnight at 4°C. The rabbit-specific
HRP/AEC IHC Detection Kit Micro-polymer (Abcam,
UK) was used to visualize the stained sections, followed
by staining with diaminobenzidine and counterstaining
with hematoxylin. The acute humoral rejection was
confirmed by the presence of DSA, linear C4d staining
in peritubular capillaries, and histologic evidence of
graft injury [44]. A well-experienced pathologist scored
the histopathologic characteristics of rejection,
including
tubulitis,
glomerulitis,
interstitial
inflammation, intimal arteritis, and peritubular
capillaritis according to the Banff lesion scores [45].
ImageJ software was used to analyze the captured
images.
DSA detection
The serum DSA titers in kidney transplant mice were
measured using the previously reported method [46]. In
brief, after pretreatment with mice Fc blocker, the cell
suspensions of kidney donor spleen were incubated with
diluted recipient serum collected on day 7 post kidney
transplantation. The cells were washed using PBS thrice
and subsequently incubated with anti-mouse IgG
(Abcam) for 15 min on ice. The unbound antibody was
washed away with PBS and the cells were analyzed by
flow cytometry. The mean channel fluorescence of each
sample was calculated using the FlowJo software (Tree
Star Inc.) and reported as a titer.
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As per the manufacturer’s protocol, the supernatants
were mixed with capture beads after 2× dilution in the
diluent. Flow cytometry samples were run on
ACSCantoII, LSRFortessa (BD Biosciences), and the
data were analyzed using the FlowJo software (Tree
Star Inc.). The median fluorescence intensity on beads
was used for statistical analysis. A standard curve was
used to extrapolate the protein concentrations.
Isolation of cells from spleen, kidneys, and graft
The tissue was gently dissociated using the gentleMACS
Dissociator (Miltenyi Biotec) in the PBS/bovine serum
albumin (BSA)- ethylene diamine tetraacetic acid
(EDTA) buffer. The buffer was prepared by mixing the
BSA stock solution with autoMACS Rinsing Solution
containing EDTA at a ratio of 1:20 (Miltenyi Biotec). The
MACS Pre-Separation Filters (Miltenyi Biotec) were used
to ensure that the dissociated tissue samples were free of
cell clumps, promoting successful MACS separation and
subsequent analysis.
Flow cytometry
Peripheral blood was collected in sodium heparin tubes.
Next, the peripheral blood mononuclear cells (PBMCs)
were isolated using Ficoll (GE Healthcare) gradient
centrifugation on the same day. CD4+ T cells and
CD19+ B cells were analyzed by Flow cytometry. In
brief, the PBMCs were labeled with anti-CD4 and antiCD19 antibodies for 30 min at room temperature in the
dark. Gates for CD4+ T cells and CD19+ B cells were
determined based on the staining with anti-mice CD4
and anti-mice CD19 antibodies (BioLegend). The
number of CD4+ T cells and CD19+ B cells in the
peripheral blood and spleen of mice after KT was
determined by FACSCalibur (BD Biosciences). FlowJo
software (Tree Star Inc.) was used for further analysis.
Statistical analysis
All statistical analyses were performed using the
GraphPad Prism 8 (La Jolla). Continuous data are
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presented as mean±standard error of the mean (SEM),
whereas frequencies are presented as proportions. Oneway analysis of variance (ANOVA) was performed for
multiple group comparisons. The Mann-Whitney U test
was performed for unpaired t test. For categorical
covariates, Chi-square tests were used to generate Pvalues. Linear regression was performed to determine
correlations. All presented P-values were calculated
with the two-tailed test; a P-value < 0.05 was
considered significant.
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SUPPLEMENTARY MATERIALS
Supplementary Figures

Supplementary Figure 1. Serum cytokine levels in transplant recipients. Serum levels of IL-12, IL-27, TNF-α, and IFN-γ (A−D) in
patients with NR (n = 30), TCMR (n = 28), and ABMR (n = 8) cohorts were measured before the anti-rejection therapy. Red dash dot line
represents the mean value. *P < 0.05 compared with NR cohorts. ABMR, antibody-mediated rejection; IFN, interferon; IL, interleukin; TNF,
tumor necrosis factor; NR, non-rejection; TCMR, T cell-mediated rejection.

Supplementary Figure 2. Higher DSA titers were observed after IL-21 administration. **P < 0.01 compared with the control. DSA,
donor-specific antibody; IL, interleukin; KT, kidney transplant.
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Supplementary Figure 3. Exogenous IL-21 alters cytokine and IL-21R expression in mice after kidney transplantation. The
levels of IFN-γ and TNF-α in (A) the peripheral blood and (B) spleen on day 7 post-transplantation were measured by CBA. The expression of
IL-21R in the spleen of (C) control, (D) KT, and (E) IL-21+KT mice on day 7 post-transplantation. Values represent the mean (±SEM). **P < 0.01
compared with the control. CBA, cytometric bead array; IFN, interferon; IL, interleukin; KT, kidney transplant; SEM, standard error of the
mean; TNF, tumor necrosis factor.
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Supplementary Table
Supplementary Table 1. Correlation between serum cytokine levels and creatinine levels at rejection onset.
Slope
P-value

IL-2
0.04035
0.5044
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IL-4
IL-6
IL-10
IL-12
IL-17
IL-21
0.004171 0.002605 0.002559 0.001074 −0.0005405 −0.01824
0.8906
0.1431
0.1787
0.9055
0.5304
0.0157
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IL-27
0.1259
0.7046

IFN-γ
TNF-α
−0.03793 0.006161
0.1285 <0.0001
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